REC-1

REC-1细胞REC-1细胞REC-1;人非霍奇金淋巴瘤细胞

Cell line name REC-1

Synonyms Rec-1; REC 1; REC1; Rec1; rec1; REC

Accession CVCL_1884

Resource Identification Initiative To cite this cell line use: REC-1 (RRID:CVCL_1884)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: LL-100 blood cancer cell line panel.

Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank).

Part of: MD Anderson Cell Lines Project.

Population: Caucasian.

Doubling time: 38 hours (PubMed=25315077); ~38 hours (ATCC=CRL-3004); ~20-40 hours (DSMZ=ACC-584).

Omics: Array-based CGH.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Omics: Virome analysis using RNAseq.

Caution: Wrongly indicated as originating from the lymph node of a 57 year old patient in ATCC.

Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.

Sequence variations

Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=16448697).

Mutation; HGNC; 11998; TP53; Simple; p.Gly245Asp (c.734G>A); ClinVar=VCV000012355; Zygosity=Heterozygous (DepMap=ACH-000068).

Mutation; HGNC; 11998; TP53; Simple; p.Gln317Ter (c.949C>T); ClinVar=VCV000450344; Zygosity=Heterozygous (DepMap=ACH-000068).

HLA typing Source: PubMed=25960936

Class I

HLA-A A*26:01,36:04

HLA-B B*35:01,57:01

HLA-C C*04:01,06:02

Class II

HLA-DQ DQA1*01:02,01:02

HLA-DR DRB1*04:03,04:03

 

Source: PubMed=25688540

Class I

HLA-A A*01,03

HLA-B B*35,57

HLA-C C*04,06

 

Source: PubMed=26589293

Class I

HLA-A A*01:01,24:02

HLA-B B*35:01,57:01

HLA-C C*04:01,06:02

Class II

HLA-DQ DQA1*01:02,01:02

DQB1*03:02,03:02

HLA-DR DRB1*01:01,01:01

 

Source: DSMZCellDive=ACC-584

Class I

HLA-B B*35:01:01,57:01:01

HLA-C C*04:01:01,06:02:01

Genome ancestry Source: PubMed=30894373

 

Origin % genome

African 1.88

Native American 0

East Asian, North 2.34

East Asian, South 0

South Asian 0

European, North 48.87

European, South 46.91

Disease Mantle cell lymphoma (NCIt: C4337)

Mantle cell lymphoma (ORDO: Orphanet_52416)

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Sex of cell Male

Age at sampling 61Y

Category Cancer cell line

STR profile Source(s): ATCC=CRL-3004; DSMZ=ACC-584; PubMed=25877200

 

Markers:

Amelogenin X,Y

CSF1PO 10,12

D2S1338 17

D3S1358 15,16

D5S818 12,13

D7S820 10,11

D8S1179 11,12

D13S317 10

D16S539 11

D18S51 14,16

D19S433 14,15

D21S11 28,29

FGA 22,23

Penta D 9,13

Penta E 7 (PubMed=25877200)

7,19 (DSMZ=ACC-584)

19 (ATCC=CRL-3004)

TH01 9,9.3

TPOX 8,9

vWA 17

 

Run an STR similarity search on this cell line

Publications

PubMed=1572647; DOI=10.1016/0888-7543(92)90303-A

Szepetowski P., Simon M.-P., Grosgeorge J., Huebner K., Bastard C., Evans G.A., Tsujimoto Y., Birnbaum D., Theillet C., Gaudray P.

Localization of 11q13 loci with respect to regional chromosomal breakpoints.

Genomics 12:738-744(1992)

 

PubMed=7504521; DOI=10.1002/gcc.2870080204

Raynaud S.D., Bekri S., Leroux D., Grosgeorge J., Klein B., Bastard C., Gaudray P., Simon M.-P.

Expanded range of 11q13 breakpoints with differing patterns of cyclin D1 expression in B-cell malignancies.

Genes Chromosomes Cancer 8:80-87(1993)

 

PubMed=8558920

Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M., Quentmeier H., Drexler H.G.

The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.

Leukemia 10:142-149(1996)

 

PubMed=14973505; DOI=10.1038/sj.leu.2403315

Prod'homme T., Drenou B., De Ruyffelaere C., Barbieri G., Wiszniewski W., Bastard C., Charron D., Alcaide-Loridan C.

Defective class II transactivator expression in a B lymphoma cell line.

Leukemia 18:832-840(2004)

 

PubMed=15126345; DOI=10.1158/0008-5472.CAN-03-3773

Ota A., Tagawa H., Karnan S., Tsuzuki S., Karpas A., Kira S., Yoshida Y., Seto M.

Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma.

Cancer Res. 64:3087-3095(2004)

 

PubMed=16448697; DOI=10.1016/j.leukres.2005.11.013

Camps J., Salaverria I., Garcia M.J., Prat E., Bea S., Pole J.C.M., Hernandez L., Del Rey J., Cigudosa J.C., Bernues M., Caldas C., Colomer D., Miro R., Campo E.

Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines.

Leuk. Res. 30:923-934(2006)

 

PubMed=16960149; DOI=10.1182/blood-2006-06-026500

Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R., Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marin M., Rosenwald A., Sugimoto K.-j., Wheat L.M., Karran E.L., Garcia J.F., Sanchez-Verde L., Prosper F., Staudt L.M., Pinkel D., Dyer M.J.S., Martinez-Climent J.A.

Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas.

Blood 109:271-280(2007)

 

PubMed=17332242; DOI=10.1182/blood-2006-11-057208

Pinyol M., Bea S., Pla L., Ribrag V., Bosq J., Rosenwald A., Campo E., Jares P.

Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis.

Blood 109:5422-5429(2007)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

 

PubMed=21746927; DOI=10.1073/pnas.1018941108; PMCID=PMC3145731

Beltran E., Fresquet V., Martinez-Useros J., Richter-Larrea J.A., Sagardoy A., Sesma I., Almada L.L., Montes-Moreno S., Siebert R., Gesk S., Calasanz M.J., Malumbres R., Rieger M., Prosper F., Lossos I.S., Piris M.A., Fernandez-Zapico M.E., Martinez-Climent J.A.

A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma.

Proc. Natl. Acad. Sci. U.S.A. 108:12461-12466(2011)

 

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)